CS MEDICA A/S Interim Report Q1 (October–December 2025)

CS MEDICA reported Q1 (Oct–Dec 2025) revenue of DKK 3.8m (vs DKK 0.3m a year earlier), gross profit DKK 1.3m (35% margin), EBIT of -DKK 1.3m (improved from -DKK 3.0m) and a net loss of -DKK 1.1m (improved from -DKK 2.9m). Total cash flow was +DKK 2.4m leaving cash of DKK 2.3m after DKK 7.1m in financing; operating cash flow was -DKK 4.6m driven by working-capital build for scaling. Order intake was DKK 5.6m with a DKK 23.8m commercial pipeline (DKK ~6.0m in active production/translation), repeat orders made up 37% of revenue, and management is focused on scaling deliveries, improving margins and reaching cash- and EBITDA-positive operations in FY2025/26.

Analysis

Market structure: CS MEDICA’s Q1 jump to DKK 3.8m revenue (from DKK 0.3m) and DKK 5.6m order intake indicate nascent commercial traction with repeat orders = 37%, primarily across EU/MENA/Mexico. Winners are European contract manufacturers, regional distributors and early-channel partners; losers are incumbents in low-cost topical therapies if CS MEDICA converts MDR-approved CBD products into scaled, reimbursable lines. The immediate supply/demand signal is constrained supply (ramp-up delays, temporary working-capital funding DKK 7.1m) meeting rising demand — pricing power is weak now (35% gross margin) but can expand if mix and scale improve over 2–6 quarters.

Risk assessment: Tail risks include MDR regulatory reversals, CBD-specific regulatory tightening in key markets, or a failed conversion of the DKK 23.8m pipeline (especially the ~DKK 6m in production) — any of which would force dilutive financing. Short-term (days–months) risk centers on liquidity: cash DKK 2.3m vs operating cash outflow DKK 4.6m implies a runway measured in weeks without new receipts or financing; medium/long-term (quarters) risks are customer concentration and margin recovery timing. Hidden dependencies: partner payment terms, inventory build-up, and EU market reimbursement decisions are binary catalysts.

Trade implications: Directional equity is warranted but size should be small and event-driven — upside if >50% of the DKK 23.8m pipeline converts within 3–6 months; downside if new financing >DKK 7–10m dilutes >10–20% of equity. Options: buy limited-duration calls to cap downside or use call spreads to exploit anticipated positive catalysts (product releases, repeat-order announcements). Cross-asset: negligible FX/commodity impact; bond investors should demand >12% yield on any new CS MEDICA debt due to short runway.

Contrarian angles: Consensus likely underestimates execution risk and overweights headline growth; the market may underprice equity if management demonstrates two consecutive quarters of positive operating cash flow. Conversely, upside may be underappreciated if repeat orders scale to >50% of revenue and margins recover to >45% within 4 quarters. Historical parallel: small EU medtechs often re-rate after two quarters of cash-flow improvement, but many fail on liquidity — the convergence of commercial validation and financing discipline will determine asymmetric outcomes.

Key Decisions for Investors

• Establish a small long position in CS MEDICA equity equal to 1–2% of the small-cap biotech sleeve (size-limited) targeting 35–50% upside over 3–6 months IF ≥DKK 6m of the DKK 23.8m pipeline is recognized; set hard stop-loss at -20% and reassess after next monthly cash update.
• If liquid options exist, buy 6-month call spreads (buy 25% OTM, sell 50% OTM) sized 0.5–1% portfolio to capture upside from pipeline conversions while capping premium; only deploy if implied vol <60% or premium <€0.10/share equivalent.
• Avoid extending credit or buying new CS MEDICA debt unless yield ≥12% and instruments include equity warrants (at least 1–2% equity kicker); monitor cash runway metrics weekly — require cash ≥DKK 5m or confirmed customer receipts covering next quarter prior to credit exposure.
• Implement a hedge via a pair trade: long CS MEDICA (as above) paired with a short 0.2 notional of Coloplast (COLO-B.CO) to neutralize European medtech beta; rebalance after 3 months or upon confirmation of >50% pipeline conversion.